Possible standard adjuvant therapies for TTP are rituximab; the monoclonal antibody against CD20 on the surface of B cells, which inhibits the production of disease-related ADAMTS13 inhibitors by depleting B lymphocytes; and caplacizumab, a humanized bivalent anti-vWF immunoglobulin fragment that inhibits the interaction between vWF multimers and platelets. This evidence concerns the gene ADAMTS13 and thrombotic thrombocytopenic purpura.